Updates are available Correction dated 2025-02-17
Click to view Correction: https://doi.org/10.1007/s12072-024-10766-3
-
Authors
Manzia, Tommaso Maria
Antonelli, Barbara
Carraro, Amedeo
Conte, Grazia
Guglielmo, Nicola
Lauterio, Andrea
Mameli, Laura
Cillo, Umberto
De Carlis, Luciano
Del Gaudio, Massimo
De Simone, Paolo
Fagiuoli, Stefano https://orcid.org/0000-0001-8308-0701
Lupo, Francesco
Tisone, Giuseppe
Volpes, Riccardo
,
-
Funding
Funding for this research was provided by:
Novartis Pharma
- License Information
-
More Information
Article History
Received: 30 March 2024
Accepted: 29 May 2024
First Online: 15 July 2024
Change Date: 17 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12072-024-10766-3
Declarations
:
: Tommaso Maria Manzia, Barbara Antonelli, Amedeo Carraro, Grazia Conte, Nicola Guglielmo, Andrea Lauterio, Laura Mameli, Umberto Cillo, Luciano De Carlis, Giuseppe Tisone, Riccardo Volpes, and Massimo Del Gaudio have no conflicts of interest. Paolo De Simone has served as an advisory board member for Novartis, Astellas, and Chiesi. Stefano Fagiuoli is on the Advisory Board and Speaker’s Bureau for AbbVie, Gilead Sciences, MSD, Novartis, Astellas, Bayer, Kedrion, and Intercept. Francesco Lupo served as an advisory board member for Novartis, Astellas, Biotest, and Chiesi.
